UK Clarifies RWD Collection Rules Under Early Access Scheme
New UK guidance says companies do not have to apply for clinical trial approval or ethics review to collect data on the clinical management of patients receiving unapproved drugs under an early access scheme. However, consent is needed where such data may have research value once collected.
You may also be interested in...
Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.
The European Medicines Agency has issued a “letter of support” to encourage ongoing efforts by an industry-led consortium to establish measurable residual disease as a surrogate efficacy endpoint in clinical studies of patients with acute myeloid leukemia.
The European Medicines Agency expects its new guideline will improve planning of confirmatory trials that include non-inferiority and therapeutic equivalence comparisons.